{"id":"brii-198","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune-related adverse events (irAEs)"}]},"_chembl":{"chemblId":"CHEMBL4650383","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BRII-198 is a humanized PD-1 inhibitor that prevents the engagement of programmed death receptor 1 (PD-1) on T cells with its ligands on tumor cells and immune cells. By blocking this inhibitory checkpoint, the drug restores T cell activation and proliferation, allowing the immune system to recognize and eliminate cancer cells. This mechanism is similar to other checkpoint inhibitors used in immuno-oncology.","oneSentence":"BRII-198 is a monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1/PD-L2) to enhance anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:43:14.189Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT04518410","phase":"PHASE2, PHASE3","title":"ACTIV-2: A Study for Outpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-19","conditions":"Coronavirus, Covid19","enrollment":4044},{"nctId":"NCT05780424","phase":"PHASE3","title":"BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-16","conditions":"COVID-19","enrollment":353},{"nctId":"NCT04501978","phase":"PHASE3","title":"ACTIV-3: Therapeutics for Inpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-04","conditions":"Covid19","enrollment":2753},{"nctId":"NCT04952402","phase":"PHASE4","title":"SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-07-09","conditions":"Covid19, SARS-CoV2 Infection","enrollment":43},{"nctId":"NCT04479644","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198","status":"COMPLETED","sponsor":"Brii Biosciences Limited","startDate":"2020-07-13","conditions":"COVID-19","enrollment":17},{"nctId":"NCT04691180","phase":"PHASE1","title":"A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198","status":"COMPLETED","sponsor":"Brii Biosciences Limited","startDate":"2021-01-05","conditions":"COVID-19","enrollment":12},{"nctId":"NCT04770467","phase":"PHASE2","title":"A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19","status":"WITHDRAWN","sponsor":"Brii Biosciences, Inc.","startDate":"2021-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04787211","phase":"PHASE2","title":"A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198","status":"COMPLETED","sponsor":"Brii Biosciences Limited","startDate":"2021-06-20","conditions":"COVID-19","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BRII-198","genericName":"BRII-198","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Biologic","firstApprovalDate":"","aiSummary":"BRII-198 is a monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1/PD-L2) to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}